Submit Deal

THERAKOS

Summary

THERAKOS Photopheresis is an extracorporeal photopheresis treatment approved by the US Food and Drug Administration.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 873 M

Avg. Deal Size£ 873 M

Market Context

Sort

Target: THERAKOS

Bidder: MALLINCKRODT PLC

2 Service Providers

5 Dealmakers

£ 873 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy